Key features and details
- Mouse monoclonal [TS81] to CD81 - BSA and Azide free
- Suitable for: IHC-P, IP, Flow Cyt, WB, ICC/IF
- Knockout validated
- Reacts with: Human
- Isotype: IgG2a
Product nameAnti-CD81 antibody [TS81] - BSA and Azide free
See all CD81 primary antibodies
DescriptionMouse monoclonal [TS81] to CD81 - BSA and Azide free
Tested applicationsSuitable for: IHC-P, IP, Flow Cyt, WB, ICC/IFmore details
Species reactivityReacts with: Human
Tissue, cells or virus corresponding to CD81.
- This antibody gave a positive result in IHC in the following FFPE tissue: Human normal lung. Flow Cyt: HAP1-WT cells.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.3
Concentration information loading...
PurityIon Exchange Chromatography
Purification notesab59477 is sterile-filtered through 0.22 µm and treated to remove endotoxins.
Our Abpromise guarantee covers the use of ab59477 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||Use a concentration of 5 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
|IP||Use at an assay dependent concentration.|
|Flow Cyt||Use 0.5µg for 106 cells.
ab170191 - Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody.
|WB||Use at an assay dependent concentration. Predicted molecular weight: 25 kDa.
This product may require non-reducing conditions for Western Blot testing, as our laboratory has been unsuccessful in detecting the protein in reducing, denaturing conditions.
|ICC/IF||Use a concentration of 1 µg/ml.|
FunctionMay play an important role in the regulation of lymphoma cell growth. Interacts with a 16-kDa Leu-13 protein to form a complex possibly involved in signal transduction. May acts a the viral receptor for HCV.
Tissue specificityHematolymphoid, neuroectodermal and mesenchymal tumor cell lines.
Involvement in diseaseDefects in CD81 are the cause of immunodeficiency common variable type 6 (CVID6) [MIM:613496]; also called antibody deficiency due to CD81 defect. CVID6 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.
Sequence similaritiesBelongs to the tetraspanin (TM4SF) family.
- Information by UniProt
- 26 kDa cell surface protein TAPA 1 antibody
- 26 kDa cell surface protein TAPA-1 antibody
- 26 kDa cell surface protein TAPA1 antibody
ICC/IF image of CD81 stained Hek293 cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab59477, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
Overlay histogram showing HAP1 wildtype (green line) and HAP1-CD81 knockout cells (red line) stained with ab59477. The cells were fixed with 4% formaldehyde (10 min) and then permeabilized with 0.1% PBS-Triton X-100 for 15 min. The cells were then incubated in 1x PBS / 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (ab59477, 1µg/ml) for 30 min at 22°C. The secondary antibody used was Alexa Fluor® 488 goat anti-mouse IgG (H&L) presorbed (ab150117) at 1/2000 dilution for 30 min at 22°C.
A mouse IgG1 isotype control antibody (ab170190) was used at the same concentration and conditions as the primary antibody (HAP1 wildtype - black line, HAP1-CD81 knockout - grey line). Unlabelled sample was also used as a control (this line is not shown for the purpose of simplicity).
Acquisition of >5,000 events were collected using a 50 mW Blue laser (488nm) and 530/30 bandpass filter.
This antibody can also be used in HAP1 cells fixed with 80% methanol (5 min), , permeabilized with 0.1% PBS-Triton X-100 for 15 min under the same conditions.
IHC image of CD81 staining in Human normal lung formalin fixed paraffin embedded tissue section, performed on a Leica Bond™ system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab59477, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
Overlay histogram showing Jurkat cells stained with ab59477 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab59477, 0.5µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG2a [ICIGG2A] (ab91361, 1µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in Jurkat cells fixed with 80% methanol (5 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.
ab59477 has been referenced in 9 publications.
- Theodoraki MN et al. Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT. Oncoimmunology 8:1593805 (2019). PubMed: 31143513
- Liu X et al. Exosomes secreted by adipose-derived mesenchymal stem cells regulate type I collagen metabolism in fibroblasts from women with stress urinary incontinence. Stem Cell Res Ther 9:159 (2018). WB ; Human . PubMed: 29895333
- Khan FM et al. Inhibition of exosome release by ketotifen enhances sensitivity of cancer cells to doxorubicin. Cancer Biol Ther 19:25-33 (2018). PubMed: 29244610
- Coulter ME et al. The ESCRT-III Protein CHMP1A Mediates Secretion of Sonic Hedgehog on a Distinctive Subtype of Extracellular Vesicles. Cell Rep 24:973-986.e8 (2018). PubMed: 30044992
- Chang GW et al. The Adhesion G Protein-Coupled Receptor GPR56/ADGRG1 Is an Inhibitory Receptor on Human NK Cells. Cell Rep 15:1757-70 (2016). ICC/IF ; Human . PubMed: 27184850
- Nardacci R et al. Autophagy plays an important role in the containment of HIV-1 in nonprogressor-infected patients. Autophagy 10:1167-78 (2014). IF . PubMed: 24813622
- Gaudin R et al. Dynamics of HIV-containing compartments in macrophages reveal sequestration of virions and transient surface connections. PLoS One 8:e69450 (2013). Human . PubMed: 23922713
- Berre S et al. CD36-specific antibodies block release of HIV-1 from infected primary macrophages and its transmission to T cells. J Exp Med 210:2523-38 (2013). PubMed: 24145510
- Mangeot PE et al. Protein transfer into human cells by VSV-G-induced nanovesicles. Mol Ther 19:1656-66 (2011). PubMed: 21750535